Effect of Oral Contraceptives on Haemostasis Variables
- 1 June 1997
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 78 (01) , 315-326
- https://doi.org/10.1055/s-0038-1657546
Abstract
Combined oral contraceptives (COCs) have effects on a large number of haemostasis variables. We have summarised literature data on effects of COCs containing 30-35 micrograms ethinyl estradiol for the third generation of progestogens (PGs): desogestrel, gestodene and norgestimate. It is concluded that about 15 variables show a shift in distribution of the order of magnitude of their interindividual variation coefficient. When comparing the third generation of PGs with the second one (norgestrel, levonorgestrel) stronger increases are noted for the former for some haemostatic variables. Also differences between desogestrel and gestodene for factor VII were apparent. It indicates that the role of PGs in the effects of COCs is significant and their design may in addition to reduction of oestrogen dosage be important in reducing haemostatic complications. The survey on molecular and cellular mechanisms by which the sex steroids might operate showed a great lack of knowledge. Only for factor XII has a functional oestrogen response element in the DNA definitely been identified. The study of molecular markers of coagulation and fibrinolysis have shown a distinct increased activation of coagulation (F 1 + 2, FPA) and fibrinolysis (PAP), and an increased fibrin turn-over (increased FDPs); platelet products are not found increased (beta TG, PF-4). The increase in fibrinolysis represent a counterforce, but individual changes in variables in coagulation and fibrinolysis do not correlate indicating independent effects and no evidence for a individually regulated balance. A first step in further research might be in understanding the increase in coagulation activation (F 1 + 2) which has so far not been satisfactorily related to changes in blood concentrations of haemostatic factors and possibly local factors.Keywords
This publication has 71 references indexed in Scilit:
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- Prospective study of exogenous hormones and risk of pulmonary embolism in womenThe Lancet, 1996
- Increased fibrin formation in blood in women above the age of 30 who are both oral contraceptive users and smokersFibrinolysis, 1996
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Epidemiology … Annotation of Esbjerg I Consensus meetingGynecological Endocrinology, 1996
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995
- Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolismContraception, 1995
- The risk of venous thromboembolism associated with low oestrogen oral contraceptivesJournal of Obstetrics and Gynaecology, 1995
- A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulationsBJOG: An International Journal of Obstetrics and Gynaecology, 1991